Skip to main content

CASI Pharmaceuticals, Inc.

CASIF
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001962738

No open-market purchases or sales by CASI Pharmaceuticals, Inc. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $17 in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding CASI Pharmaceuticals, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of CASIF: Q2 2024 compared with Q3 2024
MeasureQ2 2024Of which not filed for Q3 2024Q3 2024Change
Holders23120−2
Shares352.2K2961.32M+970.7K (+275.9%)
Value$1.94M$1.63K$8.14M+$6.20M (+320.7%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (3)

Institutions that held CASI Pharmaceuticals, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to CASIF in Q3 2024
InstitutionSharesValue% of portfolio
Woodline Partners LP30,532$188.1K0.00%
Citadel Advisors LLC22,714$135.4K0.00%
BlackRock, Inc.296$1.82K0.00%

Sold out (5)

Institutions that held CASI Pharmaceuticals, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of CASIF in Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
Howland Capital Management LLC15,072$82.9K
Simplex Trading, LLC1,042$5.00K
Qube Research & Technologies Ltd100$550
Kozak & Associates, Inc.10$53
Catalyst Funds Management Pty Ltd8$44

Not filed for Q3 2024 yet (1)

Institutions that held CASI Pharmaceuticals, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding CASIF in Q2 2024 that haven't filed for Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
BlackRock Inc.296$1.63K